Inflammation plays an important role in the genesis, progression, and manifestation of cardiovascular diseases (CVDs).
1 C-reactive protein (CRP), an acute phase protein produced by the liver, is one of the most extensively studied systemic markers of inflammation. The CRP increases within a few hours after an inflammatory trigger, peaks in 2 days, and decreases rapidly with the resolution of inflammation. Over the past three decades, extensive epidemiological and clinical evidence has linked the concentration of CRP to major CVDs.
2–4 Since the 2000s, multiple cardiology organizations across the world have recommended adding CRP as an adjunct to assess or predict risks for CVDs.
5–8 However, the role of CRP in CVDs among human populations, especially whether a causal relationship between them exists, remains unclear. This leads to substantial debates on whether CRP can be used as a therapeutic target for CVDs.
9–13